{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:29:13Z","timestamp":1762507753942,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T00:00:00Z","timestamp":1560470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T00:00:00Z","timestamp":1560470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00198-019-05020-8","type":"journal-article","created":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T11:02:36Z","timestamp":1560510156000},"page":"1855-1864","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group"],"prefix":"10.1007","volume":"30","author":[{"given":"J.P.","family":"Bilezikian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.J.F.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.P.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.T.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.R.","family":"Ebeling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Fahrleitner-Pammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Franek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Gilchrist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Valter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.A.F.","family":"Zerbini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Libanati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Chines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,14]]},"reference":[{"issue":"12","key":"5020_CR1","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17(12):1726\u20131733. \n                    https:\/\/doi.org\/10.1007\/s00198-006-0172-4","journal-title":"Osteoporos Int"},{"issue":"2","key":"5020_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1359\/JBMR.041007","volume":"20","author":"E Barrett-Connor","year":"2005","unstructured":"Barrett-Connor E, Siris ES, Wehren LE, Miller PD, Abbott TA, Berger ML, Santora AC, Sherwood LM (2005) Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res 20(2):185\u2013194. \n                    https:\/\/doi.org\/10.1359\/JBMR.041007","journal-title":"J Bone Miner Res"},{"issue":"10","key":"5020_CR3","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","volume":"164","author":"ES Siris","year":"2004","unstructured":"Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164(10):1108\u20131112. \n                    https:\/\/doi.org\/10.1001\/archinte.164.10.1108","journal-title":"Arch Intern Med"},{"issue":"6","key":"5020_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/aje\/153.6.587","volume":"153","author":"TV Nguyen","year":"2001","unstructured":"Nguyen TV, Center JR, Sambrook PN, Eisman JA (2001) Risk factors for proximal humerus, forearm, and wrist fractures in elderly men and women: the Dubbo Osteoporosis Epidemiology Study. Am J Epidemiol 153(6):587\u2013595","journal-title":"Am J Epidemiol"},{"issue":"3","key":"5020_CR5","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00198-012-2240-2","volume":"24","author":"F Borgstr\u00f6m","year":"2013","unstructured":"Borgstr\u00f6m F, Lekander I, Iverg\u00e5rd M, Str\u00f6m O, Svedbom A, Alekna V, Bianchi ML, Clark P, Curiel MD, Dimai HP, J\u00fcrisson M, Kallikorm R, Lesnyak O, McCloskey E, Nassonov E, Sanders KM, Silverman S, Tamulaitiene M, Thomas T, Tosteson AN, J\u00f6nsson B, Kanis JA (2013) The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)--quality of life during the first 4 months after fracture. Osteoporos Int 24(3):811\u2013823. \n                    https:\/\/doi.org\/10.1007\/s00198-012-2240-2","journal-title":"Osteoporos Int"},{"issue":"1","key":"5020_CR6","first-page":"27","volume":"77","author":"JP Kaukonen","year":"1988","unstructured":"Kaukonen JP, Karaharju EO, Porras M, L\u00fcthje P, Jakobsson A (1988) Functional recovery after fractures of the distal forearm. Analysis of radiographic and other factors affecting the outcome. Ann Chir Gynaecol 77(1):27\u201331","journal-title":"Ann Chir Gynaecol"},{"issue":"9","key":"5020_CR7","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00198-010-1480-2","volume":"22","author":"S Morin","year":"2011","unstructured":"Morin S, Lix LM, Azimaee M, Metge C, Caetano P, Leslie WD (2011) Mortality rates after incident non-traumatic fractures in older men and women. Osteoporos Int 22(9):2439\u20132448. \n                    https:\/\/doi.org\/10.1007\/s00198-010-1480-2","journal-title":"Osteoporos Int"},{"issue":"9156","key":"5020_CR8","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","volume":"353","author":"JR Center","year":"1999","unstructured":"Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353(9156):878\u2013882. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(98)09075-8","journal-title":"Lancet"},{"issue":"4","key":"5020_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/BF00296650","volume":"52","author":"H Mallmin","year":"1993","unstructured":"Mallmin H, Ljunghall S, Persson I, Naess\u00e9n T, Krusemo UB, Bergstr\u00f6m R (1993) Fracture of the distal forearm as a forecaster of subsequent hip fracture: a population-based cohort study with 24 years of follow-up. Calcif Tissue Int 52(4):269\u2013272","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"5020_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/BF01623274","volume":"3","author":"JB Lauritzen","year":"1993","unstructured":"Lauritzen JB, Schwarz P, McNair P, Lund B, Transb\u00f8l I (1993) Radial and humeral fractures as predictors of subsequent hip, radial or humeral fractures in women, and their seasonal variation. Osteoporos Int 3(3):133\u2013137","journal-title":"Osteoporos Int"},{"issue":"12","key":"5020_CR11","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1056\/NEJM199503233321202","volume":"332","author":"SR Cummings","year":"1995","unstructured":"Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM (1995) Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332(12):767\u2013773. \n                    https:\/\/doi.org\/10.1056\/NEJM199503233321202","journal-title":"N Engl J Med"},{"issue":"6","key":"5020_CR12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s001980050172","volume":"9","author":"MT Cuddihy","year":"1999","unstructured":"Cuddihy MT, Gabriel SE, Crowson CS, O\u2019Fallon WM, Melton LJ 3rd (1999) Forearm fractures as predictors of subsequent osteoporotic fractures. Osteoporos Int 9(6):469\u2013475","journal-title":"Osteoporos Int"},{"issue":"4","key":"5020_CR13","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","volume":"15","author":"CM Klotzbuecher","year":"2000","unstructured":"Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15(4):721\u2013739. \n                    https:\/\/doi.org\/10.1359\/jbmr.2000.15.4.721","journal-title":"J Bone Miner Res"},{"issue":"11","key":"5020_CR14","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","volume":"85","author":"DM Black","year":"2000","unstructured":"Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR, Fracture Intervention Trial (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85(11):4118\u20134124. \n                    https:\/\/doi.org\/10.1210\/jcem.85.11.6953","journal-title":"J Clin Endocrinol Metab"},{"issue":"24","key":"5020_CR15","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280(24):2077\u20132082","journal-title":"JAMA"},{"issue":"4","key":"5020_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron R, Ferrari S, Russell RG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48(4):677\u2013692. \n                    https:\/\/doi.org\/10.1016\/j.bone.2010.11.020","journal-title":"Bone"},{"key":"5020_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bone.2013.11.016","volume":"59","author":"RM Zebaze","year":"2014","unstructured":"Zebaze RM, Libanati C, Austin M, Ghasem-Zadeh A, Hanley DA, Zanchetta JR, Thomas T, Boutroy S, Bogado CE, Bilezikian JP, Seeman E (2014) Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone 59:173\u2013179. \n                    https:\/\/doi.org\/10.1016\/j.bone.2013.11.016","journal-title":"Bone"},{"issue":"1","key":"5020_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.bone.2010.04.594","volume":"47","author":"HK Genant","year":"2010","unstructured":"Genant HK, Engelke K, Hanley DA, Brown JP, Omizo M, Bone HG, Kivitz AJ, Fuerst T, Wang H, Austin M, Libanati C (2010) Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 47(1):131\u2013139. \n                    https:\/\/doi.org\/10.1016\/j.bone.2010.04.594","journal-title":"Bone"},{"issue":"4","key":"5020_CR19","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1210\/jcem.85.4.6549","volume":"85","author":"P Ravn","year":"2000","unstructured":"Ravn P, Weiss SR, Rodriguez-Portales JA, McClung MR, Wasnich RD, Gilchrist NL, Sambrook P, Fogelman I, Krupa D, Yates AJ, Daifotis A, Fuleihan GE (2000) Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab 85(4):1492\u20131497. \n                    https:\/\/doi.org\/10.1210\/jcem.85.4.6549","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"5020_CR20","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434\u20131441. \n                    https:\/\/doi.org\/10.1056\/NEJM200105103441904","journal-title":"N Engl J Med"},{"issue":"6","key":"5020_CR21","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1592\/phco.27.6.779","volume":"27","author":"JS Stroup","year":"2007","unstructured":"Stroup JS, Rivers SM, Abu-Baker AM, Kane MP (2007) Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic. Pharmacotherapy 27(6):779\u2013788. \n                    https:\/\/doi.org\/10.1592\/phco.27.6.779","journal-title":"Pharmacotherapy"},{"issue":"1","key":"5020_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24(1):153\u2013161. \n                    https:\/\/doi.org\/10.1359\/jbmr.0809010","journal-title":"J Bone Miner Res"},{"issue":"1","key":"5020_CR23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.090716","volume":"25","author":"DL Kendler","year":"2010","unstructured":"Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25(1):72\u201381. \n                    https:\/\/doi.org\/10.1359\/jbmr.090716","journal-title":"J Bone Miner Res"},{"issue":"8","key":"5020_CR24","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","volume":"101","author":"PD Miller","year":"2016","unstructured":"Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, Malouf J, Bone HG, Reginster JY, Singer A, Wang C, Wagman RB, Cummings SR (2016) Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 101(8):3163\u20133170. \n                    https:\/\/doi.org\/10.1210\/jc.2016-1801","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"5020_CR25","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"issue":"2","key":"5020_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/gme.0b013e318267f909","volume":"20","author":"JA Simon","year":"2013","unstructured":"Simon JA, Recknor C, Moffett AH Jr, Adachi JD, Franek E, Lewiecki EM, McClung MR, Mautalen CA, Ragi-Eis S, Nicholson GC, Muschitz C, Nuti R, Torring O, Wang A, Libanati C (2013) Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. Menopause 20(2):130\u2013137. \n                    https:\/\/doi.org\/10.1097\/gme.0b013e318267f909","journal-title":"Menopause"},{"issue":"12","key":"5020_CR27","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1007\/s00198-015-3179-x","volume":"26","author":"S Ferrari","year":"2015","unstructured":"Ferrari S, Adachi JD, Lippuner K, Zapalowski C, Miller PD, Reginster JY, T\u00f6rring O, Kendler DL, Daizadeh NS, Wang A, O'Malley CD, Wagman RB, Libanati C, Lewiecki EM (2015) Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporos Int 26(12):2763\u20132771. \n                    https:\/\/doi.org\/10.1007\/s00198-015-3179-x","journal-title":"Osteoporos Int"},{"issue":"7","key":"5020_CR28","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwi\u0144ski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513\u2013523. \n                    https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"5020_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jocd.2012.02.006","volume":"16","author":"MA Bolognese","year":"2013","unstructured":"Bolognese MA, Teglbjaerg CS, Zanchetta JR, Lippuner K, McClung MR, Brandi ML, H\u00f8iseth A, Lakatos P, Moffett AH, Lorenc RS, Wang A, Libanati C (2013) Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study. J Clin Densitom 16(2):147\u2013153. \n                    https:\/\/doi.org\/10.1016\/j.jocd.2012.02.006","journal-title":"J Clin Densitom"},{"issue":"6","key":"5020_CR30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/1759720X16670154","volume":"8","author":"B Langdahl","year":"2016","unstructured":"Langdahl B, Ferrari S, Dempster DW (2016) Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. Ther Adv Musculoskelet Dis 8(6):225\u2013235","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"5","key":"5020_CR31","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00198-014-2655-z","volume":"25","author":"ES Siris","year":"2014","unstructured":"Siris ES, Adler R, Bilezikian J, Bolognese M, Dawson-Hughes B, Favus MJ, Harris ST, Jan de Beur SM, Khosla S, Lane NE, Lindsay R, Nana AD, Orwoll ES, Saag K, Silverman S, Watts NB (2014) The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int 25(5):1439\u20131443","journal-title":"Osteoporos Int"},{"issue":"9041","key":"5020_CR32","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348(9041):1535\u20131541","journal-title":"Lancet"},{"key":"5020_CR33","doi-asserted-by":"publisher","unstructured":"Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (1):CD001155. \n                    https:\/\/doi.org\/10.1002\/14651858.CD001155.pub2","DOI":"10.1002\/14651858.CD001155.pub2"},{"issue":"8","key":"5020_CR34","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/jbmr.81","volume":"25","author":"E Seeman","year":"2010","unstructured":"Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E, Kearns A, Thomas T, Boyd SK, Boutroy S, Bogado C, Majumdar S, Fan M, Libanati C, Zanchetta J (2010) Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 25(8):1886\u20131894. \n                    https:\/\/doi.org\/10.1002\/jbmr.81","journal-title":"J Bone Miner Res"},{"issue":"24","key":"5020_CR35","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR, Flex Research Group (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296(24):2927\u20132938. \n                    https:\/\/doi.org\/10.1001\/jama.296.24.2927","journal-title":"JAMA"},{"issue":"5","key":"5020_CR36","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/jbmr.2442","volume":"30","author":"DM Black","year":"2015","unstructured":"Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, Lippuner K, Cummings SR, Hue TF, Mukhopadhyay A, Tan M, Aftring RP, Eastell R (2015) The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 30(5):934\u2013944. \n                    https:\/\/doi.org\/10.1002\/jbmr.2442","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-05020-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-019-05020-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-05020-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T23:26:04Z","timestamp":1592004364000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-019-05020-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,14]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["5020"],"URL":"https:\/\/doi.org\/10.1007\/s00198-019-05020-8","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"type":"print","value":"0937-941X"},{"type":"electronic","value":"1433-2965"}],"subject":[],"published":{"date-parts":[[2019,6,14]]},"assertion":[{"value":"20 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"JP Bilezikian has received research grants from the National Institutes of Health and has received consulting fees from Amgen, Radius, Ultragenyx, Alexion, and Shire. CJF Lin is a former employee and stockholder of Amgen Inc. JP Brown has received research grants from Amgen Inc., Eli Lilly, and Mereo BioPharma; received consulting fees from Amgen Inc., Eli Lilly, and Merck; and served on the speakers\u2019 bureau for Amgen Inc. and Eli Lilly. AT Wang, X Yin, and A Chines are employees and stockholders of Amgen Inc. P Ebeling has received research grants from Amgen Inc., Eli Lilly, Novartis, and Alexion, and has received consulting fees from Amgen Inc., Eli Lilly, Alexion, and Gilead. A Fahrleitner-Pammer has received consulting fees from Eli Lilly and has served on the speakers\u2019 bureau for Alexion, Amgen Inc., Eli Lilly, and Stada. E Franek has served on the speakers\u2019 bureau for Amgen Inc., Eli Lilly, and MSD. N Gilchrist has received research grants from Amgen Inc. PD Miller has received research grants from Amgen Inc., Alexion, Radius Pharma, and Regeneron. JA Simon has received research grants from AbbVie Inc., Allergan Plc, Agile Therapeutics, Bayer Healthcare LLC., Dornier MedTech, Endoceutics Inc., GTx, Inc., Ipsen, Myovant Sciences, New England Research Institute Inc., ObsEva SA, Palatin Technologies, Symbio Research Inc., TherapeuticsMD, and Tissue Genesis; has ownership in James A. Simon, MD, PC; has received consulting fees from AbbVie Inc., Allergan Plc, AMAG Pharmaceuticals Inc., Amgen Inc., Ascend Therapeutics, Bayer HealthCare Pharmaceuticals Inc., CEEK Enterprises LLC., Covance Inc., Millendo Therapeutics Inc., Mitsubishi Tanabe Pharma Development America Inc., ObsEva SA, Radius Health Inc., Sanofi S.A., Sebela Pharmaceuticals Inc., Shionogi Inc., Symbiotec Pharmalab, TherapeuticsMD, and Valeant Pharmaceuticals; has served on the speakers\u2019 bureau for AMAG Pharmaceuticals Inc., Duchesnay USA, Novo Nordisk, Shionogi Inc., and Valeant Pharmaceuticals; and is a stockholder in Sermonix Pharmaceuticals. I Valter has nothing to disclose. CAF Zerbini has received research grants from Pfizer, Amgen Inc., Sanofi, MSD, Novartis, and Lilly, and has served on the speakers\u2019 bureau for Pfizer, Lilly, and Sanofi. C Libanati is an employee and stockholder of UCB Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}